1st iPS Regenerative Medicine Product Transplanted in Japan
A Japanese startup, Cuorips Inc., has performed the first transplant of a heart muscle sheet derived from iPS cells into a patient with severe heart failure. The procedure marks a significant milestone in regenerative medicine.
Why it matters
This represents a major breakthrough in using stem cell technology to treat chronic heart conditions, potentially revolutionizing cardiac care.
Tokyo, Sept. 29 (Jiji Press)--A startup linked to the University of Osaka said Tuesday that it had transplanted a sheet of heart muscle cells made from induced pluripotent stem, or iPS, cells into a woman in her 50s with severe heart failure, marking the first transplant of a regenerative medicine product using iPS cells.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in